|
Für alle Interessieren: Melbourne, Australia; 21 March 2019: Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, announced that the term of Fujifilm Corporation’s licence option in graft-versus-host disease (GvHD) has been extended to 5:00pm Melbourne time on 19 September 2019. Dr Ross Macdonald, Cynata’s Chief Executive Officer, said “The purpose of this extension is to enable the parties to seek to accommodate certain requests made by Fujifilm in relation to structural aspects of the GvHD license agreement. We note that Fujifilm has not raised any material issues in respect of the financial, clinical or technical aspects of CYP-001 or Cynata’s core CymerusTM technology generallly Klingt jetzt eher wie ein Fussballerstatement auf Sky. Eher unspektakuläre Aktion, die mit 30% Minus bewertet wird. |
|
| aus der Diskussion: | Gewinnerbranchen der Jahre 2006 bis 2040 |
| Autor (Datum des Eintrages): | AndreasB2209 (21.03.19 06:56:16) |
| Beitrag: | 85,127 von 94,068 (ID:60156795) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |